<DOC>
	<DOCNO>NCT02323737</DOCNO>
	<brief_summary>Patients untreated extensive-stage small cell lung cancer ( SCLC ) randomly assign receive either irinotecan/cisplatin ( IP ) etoposide/cisplatin ( EP ) , The association efficacy toxicity IP regimen analyze .</brief_summary>
	<brief_title>Phase II Study Irinotecan Cisplatin Extensive-stage Small Cell Lung Cancer</brief_title>
	<detailed_description>This randomize , multicenter study . Patients randomize irinotecan/cisplatin ( IP ) etoposide/cisplatin ( EP ) treatment arm . The IP regimen consist 6 cycle irinotecan 65 mg/m2 body-surface area day 1 , 8 cisplatin 75mg/m2 body-surface area day 1 . The EP regimen consist 6 cycle etoposide 100 mg/m2 body-surface area day 1 3 cisplatin 75mg/m2 body-surface area day 1 . Cycle length two arm 3 week . The dose adjustment allow within Â±5 % per investigator discretion necessary .</detailed_description>
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Small Cell Lung Carcinoma</mesh_term>
	<mesh_term>Irinotecan</mesh_term>
	<mesh_term>Etoposide phosphate</mesh_term>
	<mesh_term>Cisplatin</mesh_term>
	<mesh_term>Camptothecin</mesh_term>
	<mesh_term>Etoposide</mesh_term>
	<criteria>Eastern Cooperative Oncology Group ( ECOG ) 0 2 A life expectancy least 3 month Measurable lesion Adequate hematologic function Infection Myocardial infarction within precede three month Symptomatic brain metastasis receive radiotherapy le 4 week Pregnancy breastfeed</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>December 2014</verification_date>
</DOC>